Treatment of tumor-bearing Sglt2-Cre; ASPSCR1-TFE3LSL/+ mice with cabozantinib using this dosing regimen significantly inhibited tumor growth (P < 0.001). The gene discussed is SLC5A2; the disease is neoplasm.